ExpreS2ion Biotech Holding AB Stock: price and insider trades · Sweden
1 insider bought €3,040 of shares over the last 90 days, the latest by Bent Frandsen, filed 09 Oct 2026.
ExpreS2ion Biotech Holding AB: what insiders have been doing
ExpreS2ion Biotech Holding AB belongs to the Health Care sector. Filings by its managers are published through Finansinspektionen. From 1 November 2025 to 1 November 2026, the disclosure feed for ExpreS2ion Biotech Holding AB logged 10 filings by 6 insiders.
Both sides are active: 5 purchases worth €18k and 1 sale worth €43, from 3 insiders and 1 insider respectively. Purchases outweigh sales by €18k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €13k, bought by Jakob Knudsen and made public on 6 May 2026. The buyers include 1 board member, 1 finance chief and 1 chief executive.
Across the 1,031 companies tracked on its exchange, the median is 9 filings; at 10 filings, this issuer sits above that mark. Our records for ExpreS2ion Biotech Holding AB go back to 2018, with 21 purchases and 28 sales on the open market in total.
The clock since the last published purchase (9 October 2026) now reads 30 days. Most trades are made public on the day they happen. The legal deadline for notifying a trade is three business days (MAR article 19).
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 10,000 shares@ SEK 1.100.042% mcap3.7% of flowAktieISIN SE0023261292FI:csv-6467d032ccf54b2d1cf7Canonical exit: 7 Jan 2027 (T+90)
- 12,000 shares@ SEK 1.190.054% mcap5.0% of flowAktieISIN SE0023261292FI:csv-316ed2f46cbdab541d1aCanonical exit: 30 Dec 2026 (T+90)
- 8,000 shares@ SEK 1.150.035% mcap3.2% of flowAktieISIN SE0023261292FI:csv-4c333c612c934df13e4dCanonical exit: 31 Dec 2026 (T+90)
- 225,615 shares0WarrantFI:csv-a2e2990c7cc1368134a1
- 225,615 shares0WarrantFI:csv-7a7a9299d43026ed6d58
- 356,234 shares0WarrantFI:csv-c23f3b5cfe44f3811143
- 89,407 shares@ SEK 1.60100.0% of flowBTU (betald tecknad unit)ISIN SE0019925017FI:A003Y213-1Canonical exit: 4 Aug 2026 (T+90)
- 156,250 shares@ SEK 1.6088.2% of flowBTU (betald tecknad unit)ISIN SE0028501155FI:A003Y068-1
- 12,500 shares@ SEK 1.60100.0% of flowBTU (betald tecknad unit)ISIN SE0028501155FI:A003Y075-1Canonical exit: 29 Jul 2026 (T+90)
- 192,125 shares@ SEK 0.00240.2% of flowTeckningsrätt/UniträttISIN SE0028501148FI:A003Y059-1
- 2,625 shares@ SEK 14.650.29% mcap100.0% of flowAktieISIN SE0023261292FI:A003S790-1
- 15,000 shares@ SEK 42.00100.0% of flowAktieISIN SE0008348262FI:A001R218-1
- AvyttringISIN EXPRES2 URFI:csv-456ce3eca134c14ba9db
- AvyttringISIN EXPRES2 URFI:csv-df22cfab9d74a5e4990e
- 19,000 shares0WarrantISIN SE0014958328FI:csv-55172b2d0ea76c7ff254
- 19,000 shares0WarrantISIN SE0014958336FI:csv-59b578a1f7e69053cf3a
- 11,100 shares0WarrantISIN SE0014958328FI:csv-cff42f67ea01fa5e8a53
- 11,100 shares0WarrantISIN SE0014958336FI:csv-671d15357069f44060c5
- 7,000 shares0TeckningsoptionISIN SE0014958328FI:csv-7de660a7b47b454554d9
- 7,000 shares0TeckningsoptionISIN SE0014958336FI:csv-a731ccc74424ce3fab01
- 2,136 shares0WarrantISIN SE0014958336FI:csv-5c553903a41b6704231f
- 2,136 shares0WarrantISIN SE0014958328FI:csv-5d249df618a982c1860e
- 22,200 shares@ SEK 12.0035.6% of flowAktieISIN SE0008348262FI:csv-a66bce781a102d59e4f2Canonical exit: 17 Jan 2021 (T+90)
- 40,200 shares@ SEK 12.0064.4% of flowAktieISIN SE0008348262FI:csv-5f4644b3b44947044f9fCanonical exit: 17 Jan 2021 (T+90)
- 4,272 shares@ SEK 12.0071.7% of flowAktieISIN SE0008348262FI:csv-3b3b3c8d1ae4855ef7eaCanonical exit: 17 Jan 2021 (T+90)
25 of 74 declarations
About ExpreS2ion Biotech Holding AB
Expres2ion Biotech Holding AB is a company focused on developing biopharmaceutical solutions. It specializes in the production of recombinant proteins for therapeutic applications.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
